Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 21, Status: Authorised

CAT: Working parties and other groups

CVMP: Working parties and other groups

CHMP: Working parties and other groups

Human medicines European public assessment report (EPAR): Imlygic, talimogene laherparepvec, Date of authorisation: 16/12/2015, Revision: 16, Status: Authorised

Agenda of the COMP meeting 7-8 October 2025

Human medicines European public assessment report (EPAR): Anzupgo, delgocitinib, Date of authorisation: 19/09/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 15, Status: Authorised

Maximum residue limits (MRL)

Scientific advice on MRL classification of chemical-unlike biological substances considered as not requiring an MRL evaluation according to Regulation (EU) 2018/782